NKTX - Nkarta, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$9.00
DETAILS
HIGH:
$9.00
LOW:
$9.00
MEDIAN:
$9.00
CONSENSUS:
$9.00
UPSIDE:
162.01%
About Nkarta, Inc. (https://www.nkartatx.com)
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Paul J. Hastings | Chief Executive Officer & Director | 1960 | $1,029,831 USD |
| Nadir Mahmood | President and Principal Accounting & Financial Officer | 1980 | $806,361 USD |
| Shawn Rose | Chief Medical Officer and Head of Research & Development | – | $515,473 USD |